

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普 华 和 顺 集 团 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

INSIDE INFORMATION DISPOSAL OF SHARES BY A SUBSTANTIAL SHAREHOLDER

This announcement is made by PW Medtech Group Limited (the “Company”) in accordance with Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

On 8 June 2015 (after trading hours), the Company received a notice from WP X Asia Medical Devices Holdings Limited (“Warburg Pincus”), a substantial shareholder of the Company, that Warburg Pincus has entered into an agreement on 8 June 2015 with Right Faith Holdings Limited (“Right Faith”), a directly wholly owned subsidiary of Mr. Marc Chan, pursuant to which Warburg Pincus has agreed to dispose of all of its shareholding in the Company, namely 327,148,418 shares of the Company (the “Disposal Shares”), to Right Faith at a price of HK\$3.0576 per Disposal Share (the “Disposal”). The Disposal Shares represent approximately 19.56% of the issued share capital of the Company as at the date of this announcement. Completion of the Disposal is subject to certain conditions that need to be satisfied. Upon completion of the Disposal, Warburg Pincus will cease to be a shareholder of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
PW Medtech Group Limited
普华和顺集团公司
Yue’e Zhang
Chairman

Hong Kong, 8 June 2015

As at the date of this announcement, the Board comprises two executive directors, namely, Ms. Yue’e Zhang and Mr. Jiang Liwei; two non-executive directors, namely, Mr. Lin Junshan and Mr. Fang Min; and three independent non-executive directors, namely, Mr. Zhang Xingdong, Mr. Chen Geng and Mr. Wang Xiaogang.